A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy

References

• Vassil AD, Murphy ES, Reddy CA, Angermeier KW, Altman A, Chehade N, . . Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology 2010;76:1251–7.
   PubMed Web of Science ®Google Scholar
• Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003;170:1872–6.
   PubMed Web of Science ®Google Scholar
• Choo R, Hruby G, Hong J, Bahk E, Hong E, Danjoux C, . . (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2002;53:269–76.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, . . Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035–41.
   PubMed Web of Science ®Google Scholar
• Higano CS. Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity. Urology 2003;61:32–8.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Tortora G, D’Armiento FP, De Rosa G, Staibano S, Autorino R, . . Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438–44.
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Kallioniemi OP, Koivula T, Harvey J, Isola J. Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol 1992;5:643–8.
   PubMed Web of Science ®Google Scholar
• Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, . . Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292–302.
   PubMed Web of Science ®Google Scholar
• Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, . . Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23:455–60.
   PubMed Web of Science ®Google Scholar
• Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, . . Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307–14.
   PubMed Web of Science ®Google Scholar
• Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, . . A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 2007;100:765–9.
   PubMed Web of Science ®Google Scholar
• Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 2003;129:165–74.
   PubMed Web of Science ®Google Scholar
• Joensuu G, Joensuu T, Nokisalmi P, Reddy C, Isola J, Ruutu M, . . A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:1439–45.
   PubMedGoogle Scholar
• Albertsen PC, Hanley JA, Penson DF, Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004;171:2221–5.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–83.
   PubMed Web of Science ®Google Scholar
• Palmberg C, Koivisto P, Visakorpi T, Tammela TL. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol 1999;36:191–6.
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448–56.
   PubMed Web of Science ®Google Scholar
• Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, . . Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–605.
   PubMed Web of Science ®Google Scholar
• Curigliano G, De Braud F, Teresa Sandri M, Renne G, Zorzino L, Scardino E, . . Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: Quality of life and surrogate markers of activity. Anticancer Drugs 2007;18:949–54.
   PubMed Web of Science ®Google Scholar
• Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, . . Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110–24.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Pelosi G, De Pas T, Renne G, De Cobelli O, Manzotti M, . . Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. Prostate 2007;67:603–4.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, . . Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–9.
   PubMed Web of Science ®Google Scholar